Proteomic and phosphoproteomics analysis of triple combination therapy in cystic fibrosis

ABSTRACT: Trikafta, a CFTR modulator, is increasingly used to treat children with cystic fibrosis (CF), but its effects remain unclear. This study evaluated the cellular mechanisms of Trikafta in young children (< 11 years) with CF using a multi-omic approach. Seventeen children with CF (median age 8.4 years, 29% female) and 12 healthy controls (median age 9.6 years, 42% female) were included. Multi omics analysis including RNA sequencing, proteomics and phosphoproteomics was performed. The proteomic and phosphoproteomics data and search results a provided here. The overall results are discussed in the associated publication.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell, Blood

SUBMITTER: Mark Graham  

LAB HEAD: Russell Dale

PROVIDER: PXD060637 | Pride | 2026-08-03

REPOSITORIES: Pride